CXCL9 was elevated in patients with autoimmune hepatitis and mice with fatty liver [40, 41], indicating that CXCL9 inhibition is a potential strategy in NAFLD treatment. Here, CXCL9 is linked to metabolic dysfunction-associated steatotic liver disease.